. "Obory neurologie a psychiatrie maj\u00ED spole\u010Dn\u00FDch mnoho terapeutick\u00FDch skupin l\u00E9\u010Div\u00FDch p\u0159\u00EDpravk\u016F a \u010Dastokr\u00E1t i pacienty. Pro p\u0159\u00EDklad uve\u010Fme u\u017E\u00EDv\u00E1n\u00ED tricyklick\u00FDch antidepresiv a p\u0159\u00EDpravk\u016F ze skupiny selektivn\u00EDch inhibitor\u016F zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu v terapii deprese po c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhod\u011B, u\u017E\u00EDv\u00E1n\u00ED tricyklick\u00FDch antidepresiv v profylaxi migren\u00F3zn\u00EDch stav\u016F, u\u017E\u00EDv\u00E1n\u00ED inhibitor\u016F cholinester\u00E1zy v terapii demence a p\u0159ekr\u00FDvaj\u00EDc\u00ED se u\u017E\u00EDv\u00E1n\u00ED antiepileptik. Pr\u00E1v\u011B antiepileptika, jako substr\u00E1ty enzym\u016F prvn\u00ED a druh\u00E9 f\u00E1ze biotransformace, maj\u00ED velk\u00FD potenci\u00E1l l\u00E9kov\u00FDch interakc\u00ED. Antiepileptika ovliv\u0148uj\u00ED aktivitu enzym\u016F prvn\u00ED a druh\u00E9 f\u00E1ze biotransformace. V tomto \u010Dl\u00E1nku se chceme zam\u011B\u0159it na l\u00E9kov\u00E9 interakce antiepileptik, antiparkinsonik, inhibitor\u016F cholinester\u00E1zy, triptan\u016F a deriv\u00E1t\u016F ergotaminu."@cs . "[5079585FC42E]" . "1212-4184" . . . "L\u00E9kov\u00E9 interakce antiepileptik, antiparkinsonik, inhibitor\u016F cholinester\u00E1zy, triptan\u016F a deriv\u00E1t\u016F ergotaminu na \u00FArovni biotransforma\u010Dn\u00EDch proces\u016F"@cs . . . . "L\u00E9kov\u00E9 interakce antiepileptik, antiparkinsonik, inhibitor\u016F cholinester\u00E1zy, triptan\u016F a deriv\u00E1t\u016F ergotaminu na \u00FArovni biotransforma\u010Dn\u00EDch proces\u016F" . "L\u00E9kov\u00E9 interakce antiepileptik, antiparkinsonik, inhibitor\u016F cholinester\u00E1zy, triptan\u016F a deriv\u00E1t\u016F ergotaminu na \u00FArovni biotransforma\u010Dn\u00EDch proces\u016F"@cs . "V" . "RIV/00843989:_____/09:00100588" . . "11" . . "Turjap, Miroslav" . "Drug interactions of antiepileptics, antiparkinsonics, cholinesterase inhibitors, triptans and ergotamine derivatives at the level of biotransformation processes"@en . "323553" . "7"^^ . . "RIV/00843989:_____/09:00100588!RIV10-MZ0-00843989" . "antiepileptic agents; antiparkinsonic drugs; cholinesterase inhibitors; cytochrome P450; drug-drug interactions"@en . . . "Obory neurologie a psychiatrie maj\u00ED spole\u010Dn\u00FDch mnoho terapeutick\u00FDch skupin l\u00E9\u010Div\u00FDch p\u0159\u00EDpravk\u016F a \u010Dastokr\u00E1t i pacienty. Pro p\u0159\u00EDklad uve\u010Fme u\u017E\u00EDv\u00E1n\u00ED tricyklick\u00FDch antidepresiv a p\u0159\u00EDpravk\u016F ze skupiny selektivn\u00EDch inhibitor\u016F zp\u011Btn\u00E9ho vychyt\u00E1v\u00E1n\u00ED serotoninu v terapii deprese po c\u00E9vn\u00ED mozkov\u00E9 p\u0159\u00EDhod\u011B, u\u017E\u00EDv\u00E1n\u00ED tricyklick\u00FDch antidepresiv v profylaxi migren\u00F3zn\u00EDch stav\u016F, u\u017E\u00EDv\u00E1n\u00ED inhibitor\u016F cholinester\u00E1zy v terapii demence a p\u0159ekr\u00FDvaj\u00EDc\u00ED se u\u017E\u00EDv\u00E1n\u00ED antiepileptik. Pr\u00E1v\u011B antiepileptika, jako substr\u00E1ty enzym\u016F prvn\u00ED a druh\u00E9 f\u00E1ze biotransformace, maj\u00ED velk\u00FD potenci\u00E1l l\u00E9kov\u00FDch interakc\u00ED. Antiepileptika ovliv\u0148uj\u00ED aktivitu enzym\u016F prvn\u00ED a druh\u00E9 f\u00E1ze biotransformace. V tomto \u010Dl\u00E1nku se chceme zam\u011B\u0159it na l\u00E9kov\u00E9 interakce antiepileptik, antiparkinsonik, inhibitor\u016F cholinester\u00E1zy, triptan\u016F a deriv\u00E1t\u016F ergotaminu." . "Neurology and psychiatry share many pharmacological treatments and oftentimes patients. The use of tricyclic antidepressants (TCAs) and selective serotonine reuptake inhibitors (SSRI) for post-stroke depression (PSD), TCAs for migraine prophylaxis, and cholinesterase inhibitors for dementia, and the overlapping psychiatric and neurologic uses of antiepileptic drugs are just a few examples. The antiepileptics have significant potential for phase I. and phase II. drug-drug interactions. These agents are substrates of phase I. and phase II. enzymes, but they also interact to both induce and inhibit these enzymes as well. In this review, we cover antiepileptic agents, antiparkinsonic drugs, cholinesterase inhibitors for dementia, and triptans and ergots for migraine headaches."@en . "Grundmann, Milan" . . . "Postgradu\u00E1ln\u00ED medic\u00EDna" . "8" . "L\u00E9kov\u00E9 interakce antiepileptik, antiparkinsonik, inhibitor\u016F cholinester\u00E1zy, triptan\u016F a deriv\u00E1t\u016F ergotaminu na \u00FArovni biotransforma\u010Dn\u00EDch proces\u016F" . . "3"^^ . . . "CZ - \u010Cesk\u00E1 republika" . "Drug interactions of antiepileptics, antiparkinsonics, cholinesterase inhibitors, triptans and ergotamine derivatives at the level of biotransformation processes"@en . . . "Dost\u00E1lek, Miroslav" . "3"^^ .